POP3:void(0)

POPOEVER Official Portal v3

MSD Dick Clark Announcement Print E-mail
Written by POPOEVER   
Monday, 07 September 2009 11:41
Article Index
MSD Dick Clark Announcement
默沙东全球总裁柯嘉瑞公开声明
All Pages

Dear Colleagues:

Today we are taking an important step in building the new Merck by announcing the structure that will enable the new company's success and the leadership team that will guide us into the future.

The structure we are adopting will build on the combined strengths of Merck and Schering-Plough to create a more customer-focused, innovative and diversified global health care company.  It also will allow us to capitalize on our greatest opportunities for growth: emerging markets, biologics and vaccines; a strong and complementary portfolio spanning key therapeutic areas; an expanded pipeline to deliver innovative medicines for patients; and promising animal health and consumer health care businesses.

The actions we are taking to enable us to reach these goals include:

  • In the new Merck, Animal Health and Consumer Health Care will operate as separate business units.
  • We will integrate across our commercial, research and manufacturing divisions to ensure that we have the dedicated focus and resources necessary to become a leader in three key areas: emerging markets, biologics and vaccines.
  • The new company will create two new franchises focused on Women's Health and Endocrine, as well as Mature Brands, to take advantage of the new Merck's broader product portfolio and robust pipeline.

Perhaps most importantly, our new company will benefit from the unparalleled industry experience of senior leaders from both Merck and Schering-Plough.  In fact, about 40 percent of Schering-Plough's senior leaders will be part of the newly combined company in executive roles.

The New Merck Executive Committee

We have assembled an experienced team that I am confident has the breadth of skills and perspectives necessary to deliver on the promise of our combined company.  I am pleased to announce today the new Merck Executive Committee, which will be operational immediately upon close of the merger:

  • Stan Barshay, executive vice president and president, Consumer Health Care
  • Rick Bowles, executive vice president and chief compliance officer
  • Willie Deese, executive vice president and president, Merck Manufacturing Division
  • Ken Frazier, executive vice president and president, Global Human Health
  • Mirian Graddick-Weir, executive vice president, Human Resources
  • Peter Kellogg, executive vice president and chief financial officer
  • Peter Kim, executive vice president and president, Merck Research Laboratories
  • Raul Kohan, executive vice president and president, Animal Health
  • Bruce Kuhlik, executive vice president and general counsel
  • Sue Capps Morris, chief of staff
  • Chris Scalet, executive vice president, Global Services, and chief information officer
  • Merv Turner, chief strategy officer
  • Open position, executive vice president and chief medical officer

New Business

Schering-Plough's animal health business is a world leader, with more than 1,000 marketed products and close to $3 billion in revenue, with strong future growth potential.  Raul Kohan, currently senior vice president and president of Intervet/Schering-Plough Animal Health, will lead the animal health business for the new Merck.

Stan Barshay, currently chairman of Consumer Health Care at Schering-Plough, will guide this important growth area for the new company on an interim basis while we conduct a search for a permanent leader.

New Functions

We are also creating two new functions at the Executive Committee level with the addition of a chief compliance officer and a chief medical officer.

The chief compliance officer is one of a number of best-in-industry approaches at Schering-Plough that will be part of the new Merck.  Through central leadership and management, this position will ensure that the new Merck leads in the important areas of ethics and compliance. I am delighted that Rick Bowles, currently senior vice president of Global Quality Operations at Schering-Plough, will fill this important role for the new company.

A chief medical officer will represent the new Merck to the medical community.  We are considering talent both internally and externally for this important new position, and will announce an appointment at a later date.

In addition to the above-named positions, I am also adding a chief of staff to my team.  Sue Capps Morris, who currently leads the Americas for Merck's Manufacturing Division, will help me efficiently manage the day-to-day business of the much larger company that will result from the merger.

You can learn more about the new Merck's Executive Committee by visiting http://pubaff.merck.com/new_merck/leadership/dick_clark.html.  I also encourage you to read our external announcement about the new company's structure at http://www.merck.com/newsroom/press_releases/corporate/2009_0831.html.

My thanks to Fred Hassan and the Schering-Plough Executive Management Team and Operations Management Team for their help and insights in determining the combined company’s structure.  Their strong leadership of Schering-Plough since we announced the merger has been invaluable, and will continue to be as we work toward the merger's close.

Division and Function Leadership Teams

In addition to the changes we are making to the top-level structure of the new company, our divisions and functions are also redefining their approaches and teams in order to support a more customer-focused, innovative and diversified company.

The people we have selected for each area's senior leadership are among the best in our industry, with proven track records.  They also have the characteristics needed to help us instill the cultural attributes we want in the new Merck: courage and candor, customer focus, and rapid and disciplined decision making.  You will be hearing more about the structure for your division or function and its new leadership from your Executive Committee member.

There is no doubt that both Merck and Schering-Plough have experienced, committed leaders who have helped shape their companies into the strong organizations they are today – and I want to thank everyone for their contributions and efforts.  The decisions I have made regarding the new company's structure and leadership team were not easy, but they were necessary in order to ensure the new Merck reaches its potential – for our customers, shareholders, patients, as well as all of you.

Next Steps

I want to emphasize that until the merger closes, Merck and Schering-Plough remain separate organizations and must continue to operate that way.  Nothing in our structures or leadership will change until we officially become the new Merck.  We remain on track to close in the fourth quarter.

In the meantime, I am counting on everyone to stay focused on our current business and 2009 priorities.  I know the changes we have announced today likely bring a mix of emotions, including new and continued unknowns.  But you have already proven how well the people of Merck and Schering-Plough can perform even in uncertain circumstances, and I need your support in continuing to do just that.

We expect to name additional key members of the new Merck’s leadership, including country managing directors, at the close of the merger.  But the timeline and steps toward making other integration-related decisions will vary by organization and location, and most of you will not see any changes until well after the merger closes. Back in March when we first announced the planned merger, we said that we expected the substantial majority of employees from Schering-Plough to remain with the new company, and that is still our expectation.  It will take time to fully integrate two companies as large as ours, and I ask for your continued patience as we work to build our new company.

After the merger closes, we will begin working within our new structure and new teams, and at that point, will be able to answer more of your questions about the new company and your place in it.  Adam Schechter and Brent Saunders, who have done an outstanding job leading integration planning for Merck and Schering-Plough, will continue to support the integration process after the close as well.

The new Merck that is beginning to take shape will be a formidable company, helping to define a new era in global health care.  We can all be proud of the achievements of both companies.  I look forward to the benefits we will bring to patients and shareowners, and to working together with you to build a bright future for the new Merck and its employees.

 

Regards,

Dick


亲爱的同事们:


今天, 我们宣布了新默沙东的架构,这是我们迈向建立全新的默沙东的重要一步。全新的领导团队相继成立,它将指引新公司走向胜利,率领我们向未来进发。

新的公司架构建立在默沙东和先灵葆雅两个公司的合力之中,它将是一家更加以客户为中心、充满创新精神和多元化的全球性医疗保健公司。这一架构将使我们有能力在以下领域把握更大的发展机遇:第一,新兴市场、生物产品、疫苗产品;第二,在关键治疗领域的强大的、补充性产品组合;第三,更为宽广的向患者提供创新药品的渠道,以及拥有光明前景的动物保健产品和消费健康保健产品。

为了实现我们的目标,我们采取了以下行动:

  • 在新默沙东组织结构中,动物健康产品和消费健康产品将作为独立的部门运行;
  • 我们将整合我们的商务、研发和生产部门,使我们能够集中精力和必要的资源,在新兴市场、生物产品和疫苗这三个领域成为领导者;
  • 新公司将设立两个新的产品组:女性健康和内分泌组,以及成熟品牌组,使得这些产品可以充分利用新公司的产品组合和强大的供应管道。

更加重要的是,新默沙东将受益于默沙东和先灵葆雅所拥有的无可比拟的丰富业内经验的高级管理精英。事实上,大约40%的先灵葆雅的高级管理者将在新合并的公司中担任高级管理职务。

新默沙东执行委员会

我们组建了一支经验丰富的团队,其成员拥有丰富的技能和敏锐的洞察力。因此,我对于新的执行委员会带领公司走向胜利充满信心。今天,我非常高兴地宣布新默沙东执行委员会,它将在合并完成时立即生效:

  • Stan Barshay,执行副总裁,消费健康产品总裁
  • Rick Bowles,执行副总裁,首席合规官
  • Willie Deese,执行副总裁,默克生产部总裁
  • Ken Frazier,执行副总裁,全球人类健康部总裁
  • Mirian Graddick-Weir,执行副总裁,人力资源部总裁
  • Peter Kellogg,执行副总裁,首席财务官
  • Peter Kim,执行副总裁,默克实验室总裁
  • Raul Kohan,执行副总裁,动物健康产品总裁
  • Bruce Kuhlik,执行副总裁,首席法务官
  • Sue Capps Morris,幕僚长
  • Chris Scalet,执行副总裁,全球服务部以及首席信息官
  • Mery Turner,首席策略官
  • 招聘中 执行副总裁,首席医学事务官

新业务

先灵葆雅在动物健康产品方面保持世界领先水平,拥有超过1000种上市产品以及近30亿美金的销售收入,并且拥有强大的增长潜力。现任高级副总裁兼Intervet/Schering-Plough动物健康产品部总裁Raul Kohan将领导新默沙东的动物健康产品部。

在消费健康产品部领导人上任之前,现任先灵葆雅消费健康产品部主席Stan Barshay将临时担任这一重要产品领域的领导职务。

新部门

我们还设立了两个新的部门,并且在执行委员会中加入了两个新的成员:首席合规官和首席医学事务官。
设立“首席合规官”这一职务,是先灵葆雅在业内有口皆碑的举措,而新的默沙东也将设立这一职位。这一职位的设立,将有助于新公司从核心领导和管理层面确保商业道德和合规性。我很高兴地宣布,现任先灵葆雅高级副总裁、全球优质运营长Rick Bowles,将担任新公司的首席合规官一职。

新设立的“首席医学事务官”将代表新的默沙东与医学界接口。我们正在考虑在内部和外部寻找这一职位的合适人选,其任命将稍后宣布。

在上述任命之外,在我的团队中增加了“幕僚长”这一职位。现任默沙东美国生产部领导人的Sue Capps Morris将出任这一职位。合并之后,公司规模将显著增加,Sue将协助我有效管理日常商务事宜。

大家可以访问以下链接了解更多关于默沙东执行委员会的信息。http://pubaff.merck.com/new_merck/leadership/dick_clark.html.

同时,我希望大家阅读公司关于新公司架构的对外公告。链接地址为:http://www.merck.com/newsroom/press_releases/corporate/2009_0831.html.

在此,我要感谢Fred Hassan和先灵葆雅的高级管理层和运营部门的领导同事,他们在制定新公司合并后的架构方面给予了大力的支持。在年初宣布合并之后,先灵葆雅的领导工作卓有成效,并将在迈向合并完成这一过程中继续保持高效。

各区域和职能部门的领导团队

除了对新公司最高层面进行调整之外,各区域和职能部门正在采取行动调整各自架构,使新公司更加以客户为中心、更具有创新性以及更加多元化。

我们为各地区选择的领导人都是拥有丰富成功经历的业内翘楚。他们都拥有帮助我们建立新公司的企业文化的素质:勇往直前、坦率正直;以客户为中心;快速、有效、训练有素的决策制定等等。在今后的时间里,大家将从相关执行委员会成员处获悉更多部门架构信息。

毫无疑问,无论是默沙东还是先灵葆雅,都拥有经验丰富、尽职尽责的领导层,正是他们把各自的公司带领到了现在的高度。借此机会,我对他们中每一个人的奉献和努力表示由衷的感谢。对新公司的架构进行调整并不是容易的决定,但是为了确保了新默沙东发挥出全部的潜能,这些调整是必要的。同时,对我们的客户、股东、患者,以及对各位员工,也至关重要。

下一步工作

我必须强调,在合并完成之前,默沙东和先灵葆雅仍然是两个独立运作的机构。在新默沙东正式成立之前,各自公司的架构和领导保持不变。我们预计合并将在今年第四季度完成。

同时,我希望公司中的每一位同事继续关注于自己的本职工作,努力完成2009年的各项任务。我知道,今天的公告可能会给大家带来各种各样的感受,这其中包括对新事务和不确定事务的感受。但是,大家已经证明了默沙东和先灵葆雅的员工可以在不确定的环境中做出优异成绩的能力。希望大家能够再接再厉。

在合并完成之时,我们将公布其余新默沙东的核心领导层的人选,包括各国家的总经理。但是,我们希望大家了解,不同地区和组织的情况各异,与合并相关的时间安排以及方式会有所不同。对于大多数同事来说,在合并完成后很长时间内可能看不到任何变化。今年三月份,当我们宣布与先灵葆雅合并后,我们曾说过希望绝大多数先灵葆雅的员工可以继续留在新的公司中工作。时至今日,我们仍然抱有同样的期望。像默沙东和先灵葆雅如此规模的两家大公司实现完全合并需要时间,因此我希望大家在建立新公司的过程中保持耐心。

合并完成之后,我们将在新的架构和团队中工作。到那个时候,我们将可以回答大家关于新公司的更多问题。Adam Schechter和Brent Saunders在领导默沙东以及先灵葆雅合并进程中做出了杰出的贡献,他们将在合并完成之后继续支持相应的工作。

即将成立的新默沙东将是一家令人敬佩的公司,她必将开启全球医疗卫生行业的新时代。我们都将为我们所做出的贡献而感到自豪。我期待我们给患者和股东带来更多的价值,我也期待与诸位共同努力,为新默沙东和广大员工创建美好的明天。

 

此致

柯瑞嘉

Trackback(0)
Comments (0)Add Comment

Write comment
quote
bold
italicize
underline
strike
url
image
quote
quote
smile
wink
laugh
grin
angry
sad
shocked
cool
tongue
kiss
cry
smaller | bigger

security code
Write the displayed characters


busy
Last Updated on Monday, 07 September 2009 11:48
 

Subscribe

Social+

Surveys

Apple or Android?
 
You are here  : Home News MSD Dick Clark Announcement